25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ATX (Amplia Therapeutics Ltd) Stock Analysis
Buy, Hold or Sell?

Let's analyze Amplia Therapeutics Ltd together

I guess you are interested in Amplia Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Amplia Therapeutics Ltd’s Financial Insights
  • 📈 Technical Analysis (TA) – Amplia Therapeutics Ltd’s Price Targets

I'm going to help you getting a better view of Amplia Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Amplia Therapeutics Ltd

I send you an email if I find something interesting about Amplia Therapeutics Ltd.

1. Quick Overview

1.1. Quick analysis of Amplia Therapeutics Ltd (30 sec.)










1.2. What can you expect buying and holding a share of Amplia Therapeutics Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
A$0.03
Expected worth in 1 year
A$-0.02
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
A$-0.05
Return On Investment
-63.3%

For what price can you sell your share?

Current Price per Share
A$0.07
Expected price per share
A$0.060019292604502 - A$0.078
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Amplia Therapeutics Ltd (5 min.)




Live pricePrice per Share (EOD)
A$0.07
Intrinsic Value Per Share
A$-0.17 - A$-0.13
Total Value Per Share
A$-0.14 - A$-0.10

2.2. Growth of Amplia Therapeutics Ltd (5 min.)




Is Amplia Therapeutics Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$7.1m$9.9m-$2.7m-38.7%

How much money is Amplia Therapeutics Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$2.8m-$3.9m$1m38.6%
Net Profit Margin-101.1%-524.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Amplia Therapeutics Ltd (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#642 / 913

Most Revenue
#394 / 913

Most Profit
#329 / 913

Most Efficient
#485 / 913
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Amplia Therapeutics Ltd?

Welcome investor! Amplia Therapeutics Ltd's management wants to use your money to grow the business. In return you get a share of Amplia Therapeutics Ltd.

First you should know what it really means to hold a share of Amplia Therapeutics Ltd. And how you can make/lose money.

Speculation

The Price per Share of Amplia Therapeutics Ltd is A$0.072. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Amplia Therapeutics Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Amplia Therapeutics Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.03. Based on the TTM, the Book Value Change Per Share is A$-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Amplia Therapeutics Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-10.2%-0.01-10.2%-0.01-14.1%-0.01-8.5%-0.01-9.5%
Usd Book Value Change Per Share-0.01-10.0%-0.01-10.0%-0.01-13.6%0.001.2%0.000.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.017.2%0.003.6%
Usd Total Gains Per Share-0.01-10.0%-0.01-10.0%-0.01-13.6%0.018.5%0.004.0%
Usd Price Per Share0.05-0.05-0.06-0.08-0.13-
Price to Earnings Ratio-6.96--6.96--5.55--17.15--19.67-
Price-to-Total Gains Ratio-7.10--7.10--5.76--70.42--33.20-
Price to Book Ratio2.75-2.75-2.19-4.12-12.11-
Price-to-Total Gains Ratio-7.10--7.10--5.76--70.42--33.20-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.04536
Number of shares22045
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.01
Gains per Quarter (22045 shares)-158.13134.33
Gains per Year (22045 shares)-632.53537.30
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-633-64345879527
20-1265-12769171581064
30-1898-190913752371601
40-2530-254218343152138
50-3163-317522923942675
60-3795-380827514733212
70-4428-444132095523749
80-5060-507436676314286
90-5693-570741267104823
100-6325-634045847895360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.015.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%7.08.00.046.7%
Dividend per Share0.00.01.00.0%1.00.02.033.3%1.00.04.020.0%1.00.09.010.0%2.00.013.013.3%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%8.07.00.053.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Amplia Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.011-0.0110%-0.015+36%0.001-902%0.000-2784%
Book Value Per Share--0.0290.0290%0.041-28%0.035-16%0.024+21%
Current Ratio--1.9841.9840%3.821-48%8.948-78%7.965-75%
Debt To Asset Ratio--0.2310.2310%0.152+51%0.119+93%0.117+97%
Debt To Equity Ratio--0.3000.3000%0.180+67%0.142+111%0.138+118%
Dividend Per Share----0%-0%0.008-100%0.004-100%
Enterprise Value--31305112.75431305112.7540%41052070.186-24%54956325.610-43%83628387.675-63%
Eps---0.012-0.0120%-0.016+39%-0.010-16%-0.011-6%
Ev To Ebitda Ratio---6.866-6.8660%-5.652-18%-17.748+158%-20.988+206%
Ev To Sales Ratio--7.0317.0310%34.512-80%170.997-96%486.873-99%
Free Cash Flow Per Share---0.013-0.0130%-0.014+3%-0.010-23%-0.010-23%
Free Cash Flow To Equity Per Share---0.015-0.0150%-0.014-9%0.001-1512%-0.001-92%
Gross Profit Margin--1.0191.0190%1.083-6%1.108-8%1.084-6%
Intrinsic Value_10Y_max---0.127--------
Intrinsic Value_10Y_min---0.173--------
Intrinsic Value_1Y_max---0.011--------
Intrinsic Value_1Y_min---0.014--------
Intrinsic Value_3Y_max---0.034--------
Intrinsic Value_3Y_min---0.045--------
Intrinsic Value_5Y_max---0.059--------
Intrinsic Value_5Y_min---0.080--------
Market Cap27932615.424-12%31346601.75431346601.7540%34644202.186-10%50907191.610-38%80271353.575-61%
Net Profit Margin---1.011-1.0110%-5.248+419%-14.886+1372%-29.779+2844%
Operating Margin---1.043-1.0430%-6.168+491%-15.106+1348%-29.938+2769%
Operating Ratio--1.9941.9940%6.285-68%15.929-87%32.132-94%
Pb Ratio2.446-12%2.7452.7450%2.188+25%4.124-33%12.109-77%
Pe Ratio-6.202+11%-6.961-6.9610%-5.550-20%-17.155+146%-19.670+183%
Price Per Share0.072-12%0.0810.0810%0.089-10%0.131-38%0.207-61%
Price To Free Cash Flow Ratio-5.446+11%-6.111-6.1110%-6.528+7%-14.712+141%-22.424+267%
Price To Total Gains Ratio-6.324+11%-7.096-7.0960%-5.762-19%-70.417+892%-33.196+368%
Quick Ratio--1.9281.9280%3.783-49%8.852-78%8.643-78%
Return On Assets---0.303-0.3030%-0.334+10%-0.248-18%-0.597+97%
Return On Equity---0.394-0.3940%-0.3940%-0.287-27%-0.685+74%
Total Gains Per Share---0.011-0.0110%-0.015+36%0.010-218%0.005-350%
Usd Book Value--7193534.6707193534.6700%9976381.380-28%8573946.822-16%5958174.096+21%
Usd Book Value Change Per Share---0.007-0.0070%-0.010+36%0.001-902%0.000-2784%
Usd Book Value Per Share--0.0190.0190%0.026-28%0.022-16%0.015+21%
Usd Dividend Per Share----0%-0%0.005-100%0.003-100%
Usd Enterprise Value--19722221.03519722221.0350%25862804.217-24%34622485.134-43%52685884.235-63%
Usd Eps---0.007-0.0070%-0.010+39%-0.006-16%-0.007-6%
Usd Free Cash Flow---3231527.040-3231527.0400%-3343610.970+3%-2502703.602-23%-2480382.513-23%
Usd Free Cash Flow Per Share---0.008-0.0080%-0.009+3%-0.006-23%-0.006-23%
Usd Free Cash Flow To Equity Per Share---0.010-0.0100%-0.009-9%0.001-1512%-0.001-92%
Usd Market Cap17597547.717-12%19748359.10519748359.1050%21825847.377-10%32071530.714-38%50570952.752-61%
Usd Price Per Share0.045-12%0.0510.0510%0.056-10%0.083-38%0.130-61%
Usd Profit---2837175.390-2837175.3900%-3932734.050+39%-2380232.232-16%-2665825.281-6%
Usd Revenue--2805227.4602805227.4600%749376.180+274%1158354.792+142%876694.959+220%
Usd Total Gains Per Share---0.007-0.0070%-0.010+36%0.006-218%0.003-350%
 EOD+3 -5MRQTTM+0 -0YOY+17 -215Y+8 -3210Y+13 -27

3.3 Fundamental Score

Let's check the fundamental score of Amplia Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.202
Price to Book Ratio (EOD)Between0-12.446
Net Profit Margin (MRQ)Greater than0-1.011
Operating Margin (MRQ)Greater than0-1.043
Quick Ratio (MRQ)Greater than11.928
Current Ratio (MRQ)Greater than11.984
Debt to Asset Ratio (MRQ)Less than10.231
Debt to Equity Ratio (MRQ)Less than10.300
Return on Equity (MRQ)Greater than0.15-0.394
Return on Assets (MRQ)Greater than0.05-0.303
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Amplia Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.607
Ma 20Greater thanMa 500.073
Ma 50Greater thanMa 1000.079
Ma 100Greater thanMa 2000.084
OpenGreater thanClose0.074
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Amplia Therapeutics Ltd

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. It also develops AMP886, which is in preclinical trial for treating solid tumors. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Fundamental data was last updated by Penke on 2025-03-28 11:10:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Amplia Therapeutics Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -101.1% means that $-1.01 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Amplia Therapeutics Ltd:

  • The MRQ is -101.1%. The company is making a huge loss. -2
  • The TTM is -101.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-101.1%TTM-101.1%0.0%
TTM-101.1%YOY-524.8%+423.7%
TTM-101.1%5Y-1,488.6%+1,387.5%
5Y-1,488.6%10Y-2,977.9%+1,489.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-101.1%-88.1%-13.0%
TTM-101.1%-190.6%+89.5%
YOY-524.8%-199.6%-325.2%
5Y-1,488.6%-336.0%-1,152.6%
10Y-2,977.9%-488.5%-2,489.4%
4.3.1.2. Return on Assets

Shows how efficient Amplia Therapeutics Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • -30.3% Return on Assets means that Amplia Therapeutics Ltd generated $-0.30 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Amplia Therapeutics Ltd:

  • The MRQ is -30.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -30.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.3%TTM-30.3%0.0%
TTM-30.3%YOY-33.4%+3.1%
TTM-30.3%5Y-24.8%-5.5%
5Y-24.8%10Y-59.7%+34.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.3%-11.9%-18.4%
TTM-30.3%-11.9%-18.4%
YOY-33.4%-11.6%-21.8%
5Y-24.8%-12.7%-12.1%
10Y-59.7%-14.3%-45.4%
4.3.1.3. Return on Equity

Shows how efficient Amplia Therapeutics Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • -39.4% Return on Equity means Amplia Therapeutics Ltd generated $-0.39 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Amplia Therapeutics Ltd:

  • The MRQ is -39.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -39.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-39.4%TTM-39.4%0.0%
TTM-39.4%YOY-39.4%0.0%
TTM-39.4%5Y-28.7%-10.8%
5Y-28.7%10Y-68.5%+39.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-39.4%-15.6%-23.8%
TTM-39.4%-15.8%-23.6%
YOY-39.4%-14.6%-24.8%
5Y-28.7%-18.0%-10.7%
10Y-68.5%-19.2%-49.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Amplia Therapeutics Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Amplia Therapeutics Ltd is operating .

  • Measures how much profit Amplia Therapeutics Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • An Operating Margin of -104.3% means the company generated $-1.04  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Amplia Therapeutics Ltd:

  • The MRQ is -104.3%. The company is operating very inefficient. -2
  • The TTM is -104.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-104.3%TTM-104.3%0.0%
TTM-104.3%YOY-616.8%+512.5%
TTM-104.3%5Y-1,510.6%+1,406.2%
5Y-1,510.6%10Y-2,993.8%+1,483.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-104.3%-193.7%+89.4%
TTM-104.3%-296.4%+192.1%
YOY-616.8%-206.9%-409.9%
5Y-1,510.6%-367.9%-1,142.7%
10Y-2,993.8%-475.9%-2,517.9%
4.3.2.2. Operating Ratio

Measures how efficient Amplia Therapeutics Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.99 means that the operating costs are $1.99 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Amplia Therapeutics Ltd:

  • The MRQ is 1.994. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.994. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.994TTM1.9940.000
TTM1.994YOY6.285-4.291
TTM1.9945Y15.929-13.935
5Y15.92910Y32.132-16.203
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9942.025-0.031
TTM1.9943.215-1.221
YOY6.2852.982+3.303
5Y15.9294.689+11.240
10Y32.1326.513+25.619
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Amplia Therapeutics Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Amplia Therapeutics Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.98 means the company has $1.98 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Amplia Therapeutics Ltd:

  • The MRQ is 1.984. The company is able to pay all its short-term debts. +1
  • The TTM is 1.984. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.984TTM1.9840.000
TTM1.984YOY3.821-1.836
TTM1.9845Y8.948-6.964
5Y8.94810Y7.965+0.983
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9843.616-1.632
TTM1.9843.879-1.895
YOY3.8214.483-0.662
5Y8.9485.950+2.998
10Y7.9656.240+1.725
4.4.3.2. Quick Ratio

Measures if Amplia Therapeutics Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 1.93 means the company can pay off $1.93 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Amplia Therapeutics Ltd:

  • The MRQ is 1.928. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.928. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.928TTM1.9280.000
TTM1.928YOY3.783-1.855
TTM1.9285Y8.852-6.924
5Y8.85210Y8.643+0.209
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9282.966-1.038
TTM1.9283.336-1.408
YOY3.7834.252-0.469
5Y8.8525.921+2.931
10Y8.6436.474+2.169
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Amplia Therapeutics Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Amplia Therapeutics Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Amplia Therapeutics Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Amplia Therapeutics Ltd assets are financed with 23.1% credit (debt) and the remaining percentage (100% - 23.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Amplia Therapeutics Ltd:

  • The MRQ is 0.231. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.231. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.231TTM0.2310.000
TTM0.231YOY0.152+0.078
TTM0.2315Y0.119+0.112
5Y0.11910Y0.117+0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2310.340-0.109
TTM0.2310.340-0.109
YOY0.1520.312-0.160
5Y0.1190.359-0.240
10Y0.1170.382-0.265
4.5.4.2. Debt to Equity Ratio

Measures if Amplia Therapeutics Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 30.0% means that company has $0.30 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Amplia Therapeutics Ltd:

  • The MRQ is 0.300. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.300. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.300TTM0.3000.000
TTM0.300YOY0.180+0.120
TTM0.3005Y0.142+0.158
5Y0.14210Y0.138+0.005
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3000.393-0.093
TTM0.3000.428-0.128
YOY0.1800.395-0.215
5Y0.1420.451-0.309
10Y0.1380.493-0.355
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Amplia Therapeutics Ltd generates.

  • Above 15 is considered overpriced but always compare Amplia Therapeutics Ltd to the Biotechnology industry mean.
  • A PE ratio of -6.96 means the investor is paying $-6.96 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Amplia Therapeutics Ltd:

  • The EOD is -6.202. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.961. Based on the earnings, the company is expensive. -2
  • The TTM is -6.961. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.202MRQ-6.961+0.758
MRQ-6.961TTM-6.9610.000
TTM-6.961YOY-5.550-1.411
TTM-6.9615Y-17.155+10.194
5Y-17.15510Y-19.670+2.516
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.202-2.074-4.128
MRQ-6.961-2.522-4.439
TTM-6.961-3.216-3.745
YOY-5.550-3.300-2.250
5Y-17.155-6.225-10.930
10Y-19.670-6.955-12.715
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Amplia Therapeutics Ltd:

  • The EOD is -5.446. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.111. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.111. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.446MRQ-6.111+0.666
MRQ-6.111TTM-6.1110.000
TTM-6.111YOY-6.528+0.416
TTM-6.1115Y-14.712+8.601
5Y-14.71210Y-22.424+7.711
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.446-2.854-2.592
MRQ-6.111-3.511-2.600
TTM-6.111-3.835-2.276
YOY-6.528-4.297-2.231
5Y-14.712-8.217-6.495
10Y-22.424-9.311-13.113
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Amplia Therapeutics Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.75 means the investor is paying $2.75 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Amplia Therapeutics Ltd:

  • The EOD is 2.446. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.745. Based on the equity, the company is underpriced. +1
  • The TTM is 2.745. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.446MRQ2.745-0.299
MRQ2.745TTM2.7450.000
TTM2.745YOY2.188+0.558
TTM2.7455Y4.124-1.379
5Y4.12410Y12.109-7.985
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.4461.874+0.572
MRQ2.7452.120+0.625
TTM2.7452.372+0.373
YOY2.1882.453-0.265
5Y4.1243.811+0.313
10Y12.1094.584+7.525
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Amplia Therapeutics Ltd.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets14,845
Total Liabilities3,427
Total Stockholder Equity11,418
 As reported
Total Liabilities 3,427
Total Stockholder Equity+ 11,418
Total Assets = 14,845

Assets

Total Assets14,845
Total Current Assets6,753
Long-term Assets8,092
Total Current Assets
Cash And Cash Equivalents 3,385
Net Receivables 3,178
Other Current Assets 190
Total Current Assets  (as reported)6,753
Total Current Assets  (calculated)6,753
+/-0
Long-term Assets
Property Plant Equipment 101
Intangible Assets 7,938
Long-term Assets Other 53
Long-term Assets  (as reported)8,092
Long-term Assets  (calculated)8,092
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities3,403
Long-term Liabilities23
Total Stockholder Equity11,418
Total Current Liabilities
Short-term Debt 1,573
Short Long Term Debt 1,492
Accounts payable 1,603
Other Current Liabilities 227
Total Current Liabilities  (as reported)3,403
Total Current Liabilities  (calculated)4,895
+/- 1,492
Long-term Liabilities
Long-term Liabilities  (as reported)23
Long-term Liabilities  (calculated)0
+/- 23
Total Stockholder Equity
Common Stock151,529
Retained Earnings -139,014
Accumulated Other Comprehensive Income -1,097
Total Stockholder Equity (as reported)11,418
Total Stockholder Equity (calculated)11,418
+/-0
Other
Capital Stock151,529
Cash and Short Term Investments 3,385
Common Stock Shares Outstanding 194,006
Liabilities and Stockholders Equity 14,845
Net Debt -1,799
Net Invested Capital 12,910
Net Working Capital 3,350
Property Plant and Equipment Gross 101
Short Long Term Debt Total 1,587



5.2. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-31
> Total Assets 
8,207
7,853
5,744
11,426
10,176
5,319
5,035
7,537
2,644
9,191
9,116
10,879
24,484
18,684
14,845
14,84518,68424,48410,8799,1169,1912,6447,5375,0355,31910,17611,4265,7447,8538,207
   > Total Current Assets 
1,156
2,395
1,227
8,393
7,971
4,624
4,883
7,375
2,644
1,252
1,178
2,936
16,533
10,509
6,753
6,75310,50916,5332,9361,1781,2522,6447,3754,8834,6247,9718,3931,2272,3951,156
       Cash And Cash Equivalents 
1,111
2,081
1,167
8,359
7,941
4,089
3,201
5,763
2,229
1,241
1,108
1,848
14,609
9,257
3,385
3,3859,25714,6091,8481,1081,2412,2295,7633,2014,0897,9418,3591,1672,0811,111
       Short-term Investments 
0
0
0
0
0
0
0
4,744
1,933
0
0
0
0
0
0
0000001,9334,7440000000
       Net Receivables 
28
267
60
33
22
26
77
132
244
34
34
1,000
1,843
1,148
3,178
3,1781,1481,8431,0003434244132772622336026728
       Other Current Assets 
17
48
26
1
29
509
1,606
1,479
170
11
35
87
81
103
190
190103818735111701,4791,606509291264817
   > Long-term Assets 
7,051
5,458
4,517
3,033
2,205
694
151
162
0
7,940
7,939
7,943
7,951
8,176
8,092
8,0928,1767,9517,9437,9397,94001621516942,2053,0334,5175,4587,051
       Property Plant Equipment 
295
225
200
167
161
160
151
162
0
2
1
5
13
185
101
101185135120162151160161167200225295
       Intangible Assets 
6,751
5,233
4,317
2,866
2,044
534
0
0
0
7,938
7,938
7,938
7,938
7,938
7,938
7,9387,9387,9387,9387,9387,9380005342,0442,8664,3175,2336,751
       Long-term Assets Other 
0
0
0
0
0
0
-151
-162
0
-7,940
0
0
-7,951
53
53
5353-7,95100-7,9400-162-151000000
> Total Liabilities 
2,228
1,779
2,549
191
404
453
1,031
908
279
527
511
539
2,636
2,849
3,427
3,4272,8492,6365395115272799081,0314534041912,5491,7792,228
   > Total Current Liabilities 
157
181
2,336
191
404
453
1,031
908
279
527
511
539
530
2,751
3,403
3,4032,7515305395115272799081,0314534041912,336181157
       Short-term Debt 
0
0
1,857
3,067
0
0
10
10
11
11
0
0
2,181
2,175
1,573
1,5732,1752,1810011111010003,0671,85700
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
11
0
0
0
2,107
1,492
1,4922,10700011000000000
       Accounts payable 
36
45
334
191
90
75
74
88
1
394
474
417
369
347
1,603
1,6033473694174743941887475901913344536
       Other Current Liabilities 
120
136
145
3,137
314
378
958
820
278
122
37
122
161
229
227
227229161122371222788209583783143,137145136120
   > Long-term Liabilities 
2,072
1,597
213
0
0
0
0
0
0
0
511
2,106
2,106
98
23
23982,1062,10651100000002131,5972,072
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
2,100
95
0
0952,100000000000000
       Long term Debt 
1,786
2,123
267
0
0
0
0
0
0
0
0
0
2,100
0
0
002,1000000000002672,1231,786
       Other Liabilities 
894
43
2
0
0
0
0
0
0
0
0
0
5
4
0
045000000000243894
> Total Stockholder Equity
5,978
6,074
3,195
11,235
9,772
4,866
4,003
6,629
2,364
8,664
8,606
10,340
21,848
15,836
11,418
11,41815,83621,84810,3408,6068,6642,3646,6294,0034,8669,77211,2353,1956,0745,978
   Common Stock
92,315
90,469
97,027
116,278
110,223
110,223
114,231
123,019
123,019
130,945
132,903
136,554
151,508
151,529
151,529
151,529151,529151,508136,554132,903130,945123,019123,019114,231110,223110,223116,27897,02790,46992,315
   Retained Earnings -139,014-134,724-128,618-125,207-122,926-120,917-120,305-116,779-109,703-104,760-99,522-105,553-94,608-85,478-88,672
   Accumulated Other Comprehensive Income 
2,334
1,083
776
510
-929
-598
-525
389
-350
-1,364
-1,371
-1,007
-1,042
-969
-1,097
-1,097-969-1,042-1,007-1,371-1,364-350389-525-598-9295107761,0832,334
   Capital Surplus 000000000000000
   Treasury Stock000000000000000



5.3. Balance Sheets

Currency in AUD. All numbers in thousands.




5.4. Cash Flows

Currency in AUD. All numbers in thousands.




5.5. Income Statements

Currency in AUD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-03-31. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue4,453
Cost of Revenue-442
Gross Profit4,0114,011
 
Operating Income (+$)
Gross Profit4,011
Operating Expense-8,436
Operating Income-4,425-4,425
 
Operating Expense (+$)
Research Development5,805
Selling General Administrative2,604
Selling And Marketing Expenses86
Operating Expense8,4368,495
 
Net Interest Income (+$)
Interest Income145
Interest Expense-78
Other Finance Cost-0
Net Interest Income67
 
Pretax Income (+$)
Operating Income-4,425
Net Interest Income67
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-8,94191
EBIT - interestExpense = -4,724
-8,941
-4,425
Interest Expense78
Earnings Before Interest and Taxes (EBIT)-4,646-8,863
Earnings Before Interest and Taxes (EBITDA)-4,560
 
After tax Income (+$)
Income Before Tax-8,941
Tax Provision-0
Net Income From Continuing Ops-4,503-8,941
Net Income-4,503
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses8,878
Total Other Income/Expenses Net-4,516-67
 

Technical Analysis of Amplia Therapeutics Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Amplia Therapeutics Ltd. The general trend of Amplia Therapeutics Ltd is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Amplia Therapeutics Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Amplia Therapeutics Ltd Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Amplia Therapeutics Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.077 < 0.078 < 0.078.

The bearish price targets are: 0.067078751857355 > 0.066 > 0.060019292604502.

Know someone who trades $ATX? Share this with them.👇

Amplia Therapeutics Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Amplia Therapeutics Ltd. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Amplia Therapeutics Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Amplia Therapeutics Ltd. The current macd is -0.00214723.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Amplia Therapeutics Ltd price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Amplia Therapeutics Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Amplia Therapeutics Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Amplia Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartAmplia Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Amplia Therapeutics Ltd. The current adx is 22.92.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Amplia Therapeutics Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Amplia Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Amplia Therapeutics Ltd. The current sar is 0.06910286.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Amplia Therapeutics Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Amplia Therapeutics Ltd. The current rsi is 45.61. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Amplia Therapeutics Ltd Daily Relative Strength Index (RSI) ChartAmplia Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Amplia Therapeutics Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 1/(-6 +6).

  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Amplia Therapeutics Ltd price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Amplia Therapeutics Ltd Daily Stochastic Oscillator ChartAmplia Therapeutics Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Amplia Therapeutics Ltd. The current cci is -2.7173913.

Amplia Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartAmplia Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Amplia Therapeutics Ltd. The current cmo is -6.06886042.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Amplia Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartAmplia Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Amplia Therapeutics Ltd. The current willr is -50.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Amplia Therapeutics Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Amplia Therapeutics Ltd Daily Williams %R ChartAmplia Therapeutics Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Amplia Therapeutics Ltd.

Amplia Therapeutics Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Amplia Therapeutics Ltd. The current atr is 0.00346312.

Amplia Therapeutics Ltd Daily Average True Range (ATR) ChartAmplia Therapeutics Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Amplia Therapeutics Ltd. The current obv is -4,759,073.

Amplia Therapeutics Ltd Daily On-Balance Volume (OBV) ChartAmplia Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Amplia Therapeutics Ltd. The current mfi is 38.73.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Amplia Therapeutics Ltd Daily Money Flow Index (MFI) ChartAmplia Therapeutics Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Amplia Therapeutics Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-11MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-30MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-31STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-02BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-03STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-06MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-26MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Amplia Therapeutics Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Amplia Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.607
Ma 20Greater thanMa 500.073
Ma 50Greater thanMa 1000.079
Ma 100Greater thanMa 2000.084
OpenGreater thanClose0.074
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Amplia Therapeutics Ltd with someone you think should read this too:
  • Are you bullish or bearish on Amplia Therapeutics Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Amplia Therapeutics Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Amplia Therapeutics Ltd

I send you an email if I find something interesting about Amplia Therapeutics Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Amplia Therapeutics Ltd.

Receive notifications about Amplia Therapeutics Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.